Diagnostica Stago S.A.S enters into Joint Research Agreement With Bristol-Myers Squibb

Partnership to develop assay for measuring concentration of the oral Factor Xa inhibitor ELIQUIS® (apixaban).
Diagnostica Stago S.A.S signe un Accord avec Bristol-Myers Squibb pour des travaux de recherche en commun

Asnières-sur-Seine, France, May 2013. 

Diagnostica Stago S.A.S (Stago), a privately held Company that provides reference tests and instrumentation in hemostasis, announced today that the company has entered a joint research agreement with Bristol-Myers Squibb Company (BMY) to develop an assay for measuring the circulating blood concentration of the oral Factor Xa inhibitor ELIQUIS® (apixaban). No commercial assay is presently available to specifically measure apixaban plasma concentration.  Terms of the agreement were not disclosed.

“Stago is pleased to have the opportunity to develop this test”, said Tristan Herve, Director of Pharmaceutical Development, “These oral Factor Xa inhibitors address an important unmet need for patients requiring anticoagulant therapy”.
Stago has already completed prototype development and will be applying for health authority approvals of the assay worldwide.  Diagnostica Stago retains 100 percent global development and commercialization rights for the assay.

About Diagnostica Stago


Stago, created in 1945, is an IVD company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis and Thrombosis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Stago products are available in more than 100 countries in the world. Stago Group had over 2000 employees worldwide.